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*rar. Jqapon 
th& b normai suhjPCtP and lo increase a~ Ih+ werily of heart 
f&lure pwgresws. Although endogenous atrial natriuretic peptide 
is thought to improve the cootdition of patients with heart failure 
by reducing preload and sfterlosd, recent Sndiny have indicated 
that a high plamta at&l nWfuretic peptide level is a pmgwstic 
predictor in patients with beart failure. 
Melhods. To evalttale the pathophysiologt mlo of endogetws 
atria! natriuretic peptide in the pulmonary circulatim, plasma 
atrial na-iw-ztic pptkte and cyclic guanosioe lwJnophmphate 
(cCMP) levels were determined in the main pulmonary artery and 
pulmonary capillary wedge region in 80 patients with chronic 
wmgestive bwl failure (New York Heart Awxiation functimtal 
aas5e5 II to Iv: 
Resulls. The plasma t&al natriuretic peptide level decreased 
rigtd6canUy fmm the main pulmonary artery to the pulmonary 
capllfary wedge region, whereas the plasma cCMP Ie, el increased 
signiscrmlly from lbe main ptdmottary artery to lhe pufmmtiuy 
capillary wedge region. In patients with mild chronic heart failure 
(n = SO), the plasma atrial natriwett peptide level orrelskd 
cmtrst. SUPS cwrelalff were not f&d in p&nlr with revere 
chronic heart failure (0 = 30). lo these patieob, the atrtal 
natriuretic peptide eximction level *as signit&ntly higher but 
thaw war no signi&xU diUermw in the CCMP production level 
h,Wee” the two erwD0 (mad and 8evere hro!lic heart raiture,. 
After the discovery by de Bold et al. (I) of potent diuretic. 
nattiuretic and vasorelaxant act;vities in atrial myocardinl 
extracts from the heart. atrial natriuretic peptide was iso- 
lated from rat and human atria (2). This peptide has been 
implicated in the regulation of water. electmlytes, blood 
v&me and blood pr&re. Recent reports (3-5) have dem- 
onstrated that it is produced and secreted not only from the 
atria but also from the ventricles of patients with hean 
fadure. Therefore. the heart is thcught to be not only a 
psmping but alsn an endocrine or@.“. 
Plasma attial natriuretic peptids cowentrations in pa- 
tients with heart failure have been reported (6-9) to be 
higher than those in normal subjects and to increase as the 
severity of heart failure progresses. Allbou~b endogenous 
atrial natriuretic peptide is thought o improve the condition 
of patients with h&t failure by reducing preload and after- 
load. recent tindings (IO) have indicated that a high plasma 
atrial natriuretic peptide level is a prognostic predictor in 
pa!ients with heart failure. It is known (I I) that the vasodi- 
iator activity of exogenous atria1 nattiuretic peptide infurion 
is markedlv attenuated in patients with severe heart failure. 
It has alsb been rep&d (12-15) that atrial natriuretic 
peptide receptors are down-regulated under high cottcentm- 
lions of the hormone. 
The purpose of the present study is I(, wduate the role of 
endogcnous atrial natriuretic peptide in the lung. which is 
rich in the hormone’s receptors (161, ofpsnents wth chronic 
heart failure. The intrxelhdar second messenger of atrial 
natliuretic pcptide is thought to be cyclic 3’S’-guano&c 
mowphosphate (&Ml’) (17): exogenourly adn+nistered 
atrial natriuretic peptide is thought to elevate plasma cGMP 
concentrations in response to its physioiogic effects, such as 
natnuresis and vasodilation (18,19J. Thus, we decided lo use 
plasma cGMP concentration as an index of the physiologic 
effccrr of endogenous atrial nalriumtic peptidc in the pulmo- 
nary arculation. 
Meth*,ds 
Study patients. Eigh:y patients with chronic congestive 
heart failure undergoing right heart cPtheteriza.tion for clin- 
ically indicated purposes were studied. Informed consent 
was ob:ained from all patients for participation in the study 
according to a protocol approved by the Committee on 
Human Investigation at our institution. There were 48 men 
and 32 women. ranging in age from 17 to 78 years (mean 58). 
Thirty-one patients had myocardial infarction ,3 months 
before enwllment. 19 had dilated cardiomyopathy, 18 had 
vaIvular heart disease, 9 had hypenrophic cardiomyopathy 
and ? bad ~vcertensive heart disease. Fiftv Daliems were 
classified in I&w York Heart Association fu&&tal class II. 
I7 patients m class 111 and I3 patients in c1as.s IV. Patients 
were divided into two groups according to functional class: 
group 1 (functional class LI; n = 50) and group II (functional 
class 111 or IV; n = 30). Forty-six patients had been trcatcd 
with dxgitrdis. 42 with diuretic agents and 40 with vasodih- 
tars. All drugs were discontinued at least IR h before the 
study. 
Study pro1oco1. After 220 nun of bed rest wilh the patient 
supine and premedication with diarepam (5 mg orally), right 
heart catheterization was performed with a 7F Swan-Ganz 
catheter. The heart rate was monitored by electrocardiogram 
IECGl. and blood oressure was measured with the cuff- 
occlusion method. ‘A Swan-Ganz catheter was inserted 
through the femoral vein into the main pulmonary artery. 
where the pressure was measured. The catheter was then 
inserted farther into the pulmonary artery, and pulmonary 
capillary wedge pressure waq measured by occluding the 
balloon. Within 2 min oi this measuremmt, blood samples 
for the mcaswancnt of plasma atrial natrwetic peptide and 
cs?MP ccncentraticxs were drawn under Ruoroscodc guid- 
ance from the main pulmonary artery and the oulmanary 
capillary wedge region. Card& outpu; was deter&ed with 
the thermodilution method immediatelv afrer blood sam- 
pling. Blood samples for the measure&nt of blood oxygen 
saturation were also drawn from ihe pulmonary capillary 
wedge region. and patients whore oxygen saturation was 
~92%. which is below the normal range 01 oxygen Saturation 
of arterial blood samples in our laboratory. were excluded. 
Measurements of plasma atrial natriwelic peptide and 
eGMP. Samples for the ssasy of plasma atrial nalriurclic 
pep!idc concentra~;on were transferred to chilled disposable 
tubes containine avrotini~l (5M) kallikrcin inactivator units/ 
ml) and ethylen~di~menctetraacetic acid (EDT.$ (I mplml). 
The blood samples were immediately placed on ice and 
centrifuged at 4’C. Aliquots of plasma were measured by 
radioimmunoassay as previously reported (9). The intro- 
assay and interassay coefficients of variation were 6.3% (n = 
6) and 9.6% ln = 6), respectively. Plasma concentrations of 
cGMP wcrc determined by radioimmunoassay I+ith a com- 
me&\ kit (Yamasa Shoyu Co. Ltd., Cboshi, Japan) (201. 
The sensitivity of the assay was 0.5 pmollml. and the 
intraassny and intcrassay coefirirzt? of v&.tion were 2.4% 
,n = 6) and 8% (n = 6). rejpectively. 
Caleulstions. Cardiac index ad menn blood presrure 
were calculated from the standard formulas, and pulmonary 
vascular resistance was calculated as follows: (Mean pul- 
monary artery pressure = Pulmonary capillary wedge 
pressurel/Cardiac output x EO(dweswm-5). For the index 
of the amoum of atrial natriuretic peptide extracted by the 
lungs. we used the following formula: (Atrial natriuretic 
peptide in the main pulmonary artery - Atrial natriurettc 
peptide in the pulmonary capillary wedge region) x Cardiac 
output X (I - hematocritllW) (ngirnin). The index of the 
amounf of cGMP produced by the lungs was dctermincd 
with the following formula: (cGMP in the pulmonary capil- 
lary wedge region - cGMP in the main pulmonary artery) x 
Cardiac output x (I - hematocrit0OiJ (nmollmtn). 
Statistical analysis. All results were expressed as the 
mean value + SEM. The least squares method was used for 
linear regression analysis. Statistical comparisons were 
made with the paired or unpaired Student I test. A p value < 
0.05 WBE considered statistically significant. 
Results 
Hemodynamic data (Table 1). Cardiac index was signili- 
candy lower in group II (functional class III or IV) than in 
group I (functional clan 11) (2.17 + 0.06 vs. 2.60 f 0.06 
literslmin per m’, p < O.OOll. In contrast, pulmonary 
capi!lary wedge pressure was significantly higher in group 
II than in group I (2i).2 + I.1 vs. 9.1 ? 0.5 mm Hg, p < 
O.Wl). Puimonary ~abcular resistance was also significantly 
higher in group 11 than in group 1 (214 2 I8 vs. I52 e 
8 dynes.sxm-‘, p < 0.05). 
Plasma cyclic guanosine monophosphrde (cGMp) and atrial 
natriurctic pcptide levels. The levels in the main pulmonary 
artery of patients in group II were significantly higher than 
values in patients in group I (atrial natriuretic peptide. 490 -L 
81 vs. I28 z 8.8 pgiml. p < O.OOl;cCMP, 9.4 + 0.64~~. 5.3 
? 0.35 pmollml. p < O.CNll). Plasma atrial natriuretic peptide 
concenlration in the main pulmonary anery correlated sig- 
nificantly with the pulmonary capillary wedge pressure for 
both group I and group II lgroup I, r = 0.78, p < 0.001: group 
II, r = 0.58. p < O.OOll. Although the plasma cGMP 
concentration correlated positively with the plasma atrial 
natriuretic peptide level in the main pulmonary artery m 
group I patients (r = 0.11, p < 0.001) (Fig. I). there was no 
sl;ch ccxzlation in group II (Fig. 2!. 
The plasma atrial natriwetic ptptide concentration de- 
creased significantly from the mam puhnonar~ anery LO rhe 
pulmonary capillary wedge region in both groups I and II 
(group I. I28 + 8.8 to III c 8.1 @ml. p < 0.001; group Il. 
490 2 81 to 332 + 49 pgiml. p c 0.W IFig. 31. In contrart. 
the plasma cGMP level increased significantly from the 
main mdmonarv anew to the pulmonary capdlary wedge 
regiod in both ~rruups i and II (group 1. 5:3 ~‘0.35 ;O 7 6.2 
0.56 omollml. D < 0.001: srouo II. 9.4 + 0.64 to I? + 
I.1 pk#ml, p > 0.031) (Fig. 3): 
Correlation between atrIal natrluretic peP!k!~ extraction 
and cGMP prodttction level in the pulmonary circrlation. in 
group 1, there was a significant positive correlakm (I = 0.78. 
p < O.M)l) (Fig. 4). In contrast. there was no significant 
correlation between the two measurements in group II. and 
all the data from these patients were localized at the right 
side of the linear regres&n line from those of group I (Fig. 
5). Therefore. the molar ratio of cGMP production to atrial 
natriuretic peptide exttxii,w in the pulmonary circulation in 
group II was significantly lower than that in group I(88 + I6 
vs. K?S 5 41. p c 0.001) (Fig. 6). 
Figure 1. Correlation between plasma atnal natnuetx peptlde 
(ANP)andcyclicguanosine monophosphnte(eGUP)concentr~t,tlons 
in the main pulmonary anery in group I tfunctionat class 111. 
Discussion 
Plasma .,?MP concwtratii a~ 88 index of phyeio!ogtc 
et%& of al&l natrioretic peptide. It is very difficult to 
evaluate the clinical significance of endogenous atriai natri- 
ure:!c prp!!de in pa:ieats with hertt frilcre. In fact, no repan 
on wch an evaluation has been published thus far. Theoret- 
ically. an effective way to investigate the physiologic c%cts 
of endogenous atrial natriuretic peptide is to use antibodies 
agaicst the hormone or i!s receptor (21,221. Although such a 
method is possible in animals. it is almost impossible in 
humans. -specially patients sith hext failure. The intracel- 
lular second messenger of atria: natriuretic peptidc is 
thought to he cyclic guanosine monophosphate WXP) (17). 
and it is believed that wme intracellular cGMP leaks out of 
the target cells; an in vitro experiment t23.24) dewmstratcd 
that the cGMP concentiation h the me&m rises with an 
increase in the intracellular concentmtiun of cGMP Exogc- 
nously administered atria1 natriuretic peptide was found 
(18.19) to elevate the plasma cGMP concentration in actor- 
dance with its phyaiclogic elects. such as natriuresis and 
varodil:non. Thus, we decided to LX the piasma cGMP 
concentration as an index of the phy&lc$c effects of &al 
natriuretic peptide. 
Figure 2. Comparison between plssma atrial natriuredc peptide 
[ANP)andcyclicguanosi,le monophorpbate(cGMPIconcentmtions 
in the main pulmonary anery in group II @mcrianal class 111 or IV). 
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iigure 3. Plasma atnal nmhiuredc peptide 64NP) 
and CYChC guanoSine monophaapha,e (CGMP) eon- 
cenlr&ns in the main pulmonary afiery IPAI and 
pulmonary capillary wedge region (PC) in grwp I 
~funcrional class II) and group II (functional dar; ir: 
or IV). Ip < O.WI. 
Relation between plasma atrial natriuretic peptide and 
eGMP. Previous studies (25-27) have indicated a poshive 
correlation between the plasma atrial natriuretic peptide and 
cGMP concenlrations in :~a ‘ems whh hear1 faik. In the 
present study. rhe plasmi! ,;GM? cnnccntr&lion correlaled 
with the plasma atrial naviuretic peptide level in patents 
with mild hean failure (grow IL In our oreliminarv studv. 
there was also B pa& &r&km bet&en plarrk a.&4 
natriuretic peptide and cGMP concentration in &ems with 
severe a& heart failure whose levels of a& natriuretic 
peplide are high. lo patienls with sewre chronic heart failure 
@row II), however, no such correlation was observed. and 
the LGMP concentration reached a plateau despite high 
concentralions of atrial natriurelic peptide (Fig. 2). These 
resulls indicate that cGMP production in the targel cells of 
atrial nalriuretic peptide. such as vascular smooth muscle, 
may be attenuated in patienls with severe chronic heart 
fadure, who conlinue to have high levels of atrial natriure~ic 
peptide. 
Atrial natriurdic peptide extrartion and cGMP pradrzz- 
don. Positive correlalion between the pulmonary capillary 
wedge pressure and the plasma atrial natriuretic prptide 
concentration suggests that release of the hormone from the 
heart is regulated by the preload (9). The significant decrease 
in plasma dwial nawiuretic pepdde level from the man 
pulmonary artery to the pulmonary capillary wedge region 
would indicate the exlrdcdon of the hormone in the Pulmo- 
nary circularion. We have previously repor?ed (9) (hat atrial 
natriuretic pepdde was metabolized in the pulmonary circu- 
lation in patienls wilh left-sided heart failure. Recently, 
Obala et al. (28) also reported that atrial natriuretic o&de 
was removed by Ihc I& in padents with mitral sienbsk, as 
measured by blood sampling in both the pulmonary anely 
and the pulmonary capillary wedge region. We assumed that 
data from the pulmonary capillary wedge region could 
substitute for data Srom the pulmonary vein, because our 
preliminary study showed no apparent di&rence between 
pept~de xtraction level wal higher in patients with severe 
than :n patients with mild heart laiiure. but there uas no 
significant difference in the cGMP productloo level. Tbere- 
fore. the ratio of cGMP praluction to atrlal natnuretic 
prptide extraction in the pulmonary arcuiation :vas Fignifi- 
cantl) lower for patients with severe hean failure. In addi- 
lion. the pulmonary vascular resistance was hipher for 
patient\ with sesiiie ksn for those with m;:d bcai; hilure. 
Tw rpes of arrial nnrriareric ,wptide rewp~ors ore 
inown. one is coupled to q,usnylate cyclasc and ihc otbcr is 
uwolved in atrial natriuretic peptide clearance (17.30). Their 
dlsrnbutlons in the body are probably also diTerent The 
possib~ht!. of a hmit of substra!e a\,tilability ior cCMP 
production due to metabolic defictt. or locai Ischen,ia due to 
sustained mterstitial edema, in patios w;:h severe chronic 
heart failure cannot be neglected. Nevenheltz the rcsullJ 
of this rtudy suggest that down-regulation of :here &al 
the plasma atrial nairiuretic peptide and cGMP concentra- 
tions from these two regions in patients with an atrial septal 
defect. In addition, blood from the pulmonary capillary 
wedge region was arterial blaod, with a mean oxygen sat”- 
ration of 95.5%. The present study shows a sigmficant 
increase in plasma cGMP concentration from the main 
pulmonary artery to the pulmonary capillary wedge region in 
patients with heart failure. 
These results indicate that atrial natriuretic oeotide is 
extracted 2nd cGMP is produced in the pulmo&y &da- 
tion. Indeed, there was a significant positive correlation 
between the calculated atrial natriureric peptide ewaction 
level and the calculated cGMP production level in the 
pulmonary circulation of patients with mild heart failure 
(gmup I). From these results, it is postulated that endoge- 
nous atrial natriuretic veptide functions as B pulmonary 
vasodilator by binding -:a- its receptors in the &nonur) 
vascular bed, at least in pa!ients with mild heart failure. 
Considering that the lung k rich in atrial natriuretic peptide 
receptors and that a high pulmonary clearance rate for the 
hormone bar been reported. it is powble that the hormone 
has a physiologic function by binding with its receptors in 
the pulmonary vascular bed in patients with heart failure. 
Labat et al. (29) reported that exogenous atrial natriuretic 
peptide dilates isolated pulmonary vascular prwxrations in 
humans; therefore, endogenour atrial ttatrw. ic peptlde 
may vasodilate the pulmonary vascular red ?I r: 1’ ‘nts with 
natriurettc peptide receptors coupled to guanylatr :vclase in 
the pulmonary vascular bed may occur. and this is suspected 
to have a physiologic riguifiance in severe heart failure. 
Although endogenous atrial natriuretic peptide is thought to 
improve the condition of patients with hean failure, recent 
findinrs t IO) have indicated that a high plarma level of the 
horn&e is o prognostic predictor in iatients with heart 
fadwe. Thus. in patients with severe heart failure. a high 
concentration of endogenous atrial natriurctic peptide may 
fail to exert its compensatory function in the pulmonary 
circulation. probably because of the down-regulation of its 
pulmonary receptorn coupled to yanylate cyclase. 
Clinical bn@kzdionr. !n patients with eart f&ii. ztrial 
natr!uretic peptide probably performs com~nsatory func- 
tions such as diuresis. natriuresis. vasodilation and supprer 
sion of renin and aldostemnc secretion. However, it is 
difficult to evaluate the clinical significance of endogenous 
levels of the peptide in patients with hean failure. Recent 
animal experiments (221 in rats with heart failure showed an 
increase in left ventricular end-diastolic pressure after the 
administration of monoclonal antibodies against atrial natri- 
urcdc pcptide. in tbc prescrd study, we examiued the 
relation between atrial natriuretic peptide extraction and 
cGMP production in the pulmonary vascular bed with re- 
spect to vasodilation. one of the physiologic effects of atrial 
natriuretic peptide. Our results indicate that in patients with 
mild bean failure, an increase in the endogenous atrial 
lnatruretic peptide level may compensate for the heart 
failure by reducing the pulmonary vascular tone. However. 
in patients with severe heart failure. where a high level of 
plasma atrial natriure!ic peptide is sustained for a long period 
of time, a down-regulation of&al natriuretic peptide recep 
n&i heurt failure. ton in the pulmonary vascular bed mnay occur. Indeed. 
In patients wcih swc~c hrurt failure. thc;e was no signif- Schiffrin (14) baa demonstrated that atrial natriuretic pep- 
icant correlation between the plasma atrial natriuretic pep- tide-binding sites on platelets decrease in patients with 
tide and cGMP concentrations or between the ctrial natri- severe congestive heart failure. SchitTrin and St-Louis (13) 
uretic peptide extraction level and the cGMP production have also indicated that the mesenteric vascular atrial natri- 
Iwe: ia the pulmonery cilwlatinn The wial rxriuret~c uretlc yeptid- rcce?rors are down-regclated in WCA-sd 
hypertensive rats with a high plnr.x z!rc! namuretic pep- 
ride concentration. 
The other compensatory effects oiabial natriuretic pep- 
tide in heart failure, such as diuresis and the suppression of 
win and aldosterone secretion, were not examined in this 
study. However. because atrial natrtur&c peptide IS a 
receptor-mediated hormone, it is reasonable to assume that 
a down-regulation of the atrial natriuretic peptide receptors 
develops in chronic heart faiiure, where a high level of atrial 
natriuretic peptide is sustained for a long period aftime. The 
observation that patients with chronic heart failure with a 
high plasma atrial natriuretic peptide concentration have a 
poor prognosis snppons this hypothesis. 
Limitations. In the present srudy, blood samples were 
drawn from the pulmonary capillary wedge region to confirm 
the extraction ofatrial natriuretic peptide and the production 
of cGMP in the oulmonarv circulation. Samoles were drawn 
in this way be&e it is not ethical to pe&rm transseptal 
catheterization through the fossa ovalis to obtain blood 
samples lrom the pulmonary vein. However, the blood 
withdrawn from tie pulmonary capillary wedge position may 
achieve a limited sampling window of the pulmonary bed 
compared with that of pulmonary ve”ous blood. 
Conch&m. In patients with mild heart failure, endagc- 
nous atrial natriuretic peptide is extracted and cGMP i( 
produced in the pulmonxy circukdion, and it is thought that 
arrial natriureric peptide may caux vasodilation of the 
pulmorxry vasculature. In contrast, I” patients with revere 
hea;. izi!xe, in whom a high plasma concentration of atrial 
natriurelic peptide is sustained over a long period of time, 
down-regulation of the hormone’s recepton may occur, so 
that compensation by atrial natriuretic peptide is probably 
negated in the pulmonary circulation. 
